Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01676961 · ClinicalTrials.gov registry record · Phase 2
Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01676961 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 5 participants.
The verdict
NCT01676961, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase II trial studies how well romiplostim works in increasing low platelet counts in patients with multiple myeloma receiving chemotherapy. Romiplostim may cause the body to make platelets after chemotherapy
Interventions
- BIOLOGICAL romiplostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01676961
The ClinicalTrials.gov registry entry for NCT01676961 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which romiplostim is the first listed.
NCT01676961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01676961 about?
NCT01676961 is a clinical study titled "Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy". This phase II trial studies how well romiplostim works in increasing low platelet counts in patients with multiple myeloma receiving chemotherapy. Romiplostim may cause the body to make platelets after chemotherapy
What is the current status of trial NCT01676961?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2013-01. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01676961?
The interventions under investigation include: romiplostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT01676961?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.